Navigation Links
Spectral announces 2008 financial results
Date:3/12/2009

ing of year (2,687) (1,021) ---------------------------- Deficit - End of year (4,189) (2,687) ---------------------------- ---------------------------- Basic and diluted loss per common share (0.06) (0.07) ---------------------------- ---------------------------- Weighted average number of common shares outstanding 24,118,424 24,117,333 ---------------------------- ---------------------------- Spectral Diagnostics Inc. Statements of Cash Flows For the years ended December 31, 2008 and 2007 ------------------------------------------------------------------------- (in thousands of dollars) 2008 2007 $ $ Cash provided by (used in) Operating activities Loss and comprehensive loss for the year (1,502) (1,666) Items not affecting cash Amortization 592 536 Amortization of commercial instruments included in cost of sales 76 63 Loss on disposal of property, plant and equipment - 46 Writeoff of purchased technology and trademarks - 66 Stock-based compensation expense 110 117 Interest on convertible note payable 164 165 Changes in non-cash working capit
'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
2. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
3. Spectral announces third quarter 2008 results
4. Spectral to bring anti-sepsis therapy to the U.S. market
5. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
6. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
7. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
8. Spectral and Toray expand collaboration to include new geographic territories
9. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
10. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
11. Spectral announces 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 According to a new market ... global orthobiologics market was valued at USD 3,754.6 million in ... 5,519.9million in 2019at a CAGR of 5.9% from 2013 to ... and above is afflicted by bone and joint disorders, and ... 2020. This has and will continue to increase the demand ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Only Collagen-Based Filler Proven To Last Through One Year , ... Ortho Dermatologics today announced that the U.S. Food and Drug ... safety data through 12 months for EVOLENCE(R), a collagen-based dermal ... and folds, such as nasolabial folds. , , To ...
... RAMAT GAN, Israel, June 8 EarlySense announced ... cleared for,marketing by the U.S. Food and Drug Administration ... Dutch notified body, in accordance with the,EC-Directive 93/42/EEC. Both ... home, hospital or clinical setting. In November 2007, EarlySense,announced ...
... under the Pacific Ocean, could provide a powerful clean-up ... issue of the journal, Microbiology , Professor Gejiao ... Wuhan, PR China describe how a particular strain of ... effective in removing manganese from solutions, converting it into ...
Cached Biology Technology:Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 2Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 3Photos: FDA Approves 12-Month Labeling Update for EVOLENCE(R) Collagen-Based Facial Filler 4EarlySense's EverOn(TM) System Receives FDA Clearance and CE Mark Certification 2
(Date:8/29/2014)... German . ... cycle on Earth and in biological wastewater treatment plants. ... on nitrite as their source of energy. An international ... at the University of Vienna, has now shown that ... of energy. The oxidation of hydrogen with oxygen enables ...
(Date:8/29/2014)... This news release is available in German . ... of chemical signals between organisms is considered the oldest ... social interactions between conspecifics, for example, the sexual attraction ... trigger social responses and to coordinate reproductive behavior in ... at the University of the Algarve in Faro, Portugal, ...
(Date:8/29/2014)... Some species of marine phytoplankton, such as the prolific ... vitamin B1 (thiamine), researchers have discovered. The finding contradicts ... many other eukaryotic microbes depend on scarce supplies of ... really different way to think about the ocean," says ... The ISME Journal paper with CIFAR fellows ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Ready for mating at the right time 2Ready for mating at the right time 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
... that some brain tumours in larvae of the fruit fly ... cells to grow. The removal of some of these genes ... are crucial for tumour development. The study, headed by ICREA ... Science . One of the characteristics of ...
... mankind,s migration from Africa to the New World, and the ... international study that for the first time will dig deep ... a mile) down under 300 meters (about a fifth of ... researchers will look back in time to collect a massive ...
... University of Exeter have developed a new approach to ... up the process of finding vaccines. Dr Andrea ... the university,s Cornwall Campus, has pioneered a simple screen ... gene structures of pathogenic* bacteria. The screen allows ...
Cached Biology News:Some brain tumors mimic the genetic program of germline cells 2Back to the dead (sea, that is) 2Finding new ways to tackle environmental diseases 2
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Yeast tRNA 50 l...
Biology Products: